Monoclonal antibodies for treating COVID-19

Area of Science:

• Virology
• Immunology
• Pharmacology

Background:

• COVID-19 poses a significant global health threat.
• Effective treatments are crucial for managing mild to moderate cases and preventing severe disease.
• Monoclonal antibodies offer a targeted therapeutic approach.

Purpose of the Study:

• To evaluate the role of bamlanivimab and casirivimab-imdevimab in treating COVID-19.
• To assess their efficacy in preventing progression to severe disease in at-risk outpatients.
• To review current safety and efficacy data.

Main Methods:

• Review of existing clinical trial data and regulatory authorizations.
• Analysis of the mechanism of action of virus-neutralizing monoclonal antibodies.
• Assessment of patient populations eligible for treatment.

Main Results:

• Bamlanivimab and casirivimab-imdevimab are authorized for mild to moderate COVID-19 in specific outpatient settings.
• Early treatment may reduce the risk of severe disease progression.
• Data on safety and efficacy remain limited.

Conclusions:

• These monoclonal antibodies represent a potential treatment option for early-stage COVID-19 in high-risk individuals.
• Further research is needed to fully establish their long-term safety and efficacy profile.
• Current authorizations exclude hospitalized patients with advanced disease.